|
|
|
|
|
|
 |
|
 |
|
|
Stocks to Watch – Tianli Agritech Inc. (NASDAQ: OINK)
Tianli Agritech, Inc. (Tianli) is a Company involved in the business of research and development. It is also engaged in raising, breeding and selling hogs in the People’s Republic of China. This was established on November 9, 2009. It primarily focuses on growing hogs for sale for breeding and meat purposes. By the year 2009, it owned and operated eight commercial farms in Wuhan city (Wuhan). Then, on October 2011, it acquired land use rights and facilities in the following areas:
- Osmanthus Village Industrial Park
- Xiangfeng Town
- Laifeng County
Its farms are focused in raising and selling hogs for both breeding and meat purposes. The farms have an annual production capacity of approximately 110,000 hogs. It also conducts genetic, breeding and nutrition research. It also has an animal nutrition research which is composed of the research and development of biofeed premix (premix) for use in its hog farms.
Tianli is also a holding company incorporated in the British Virgin Islands. Its fully-owned subsidiary is one of the largest commercial hog farming companies in Wuhan and Hubei. In fact, when the Company entered the hog breeding business, it built the first ever hog farm. The Company also conducts genetic, breeding and nutrition research to improve its production capabilities. Moreover, its animal nutrition research consists of the research and development of biofeed premix (“premix”) for use in its hog farms. The Company coordinates with a local institute in developing products to improve feed to meat conversion ratios, improve the health of our hogs and reduce our feeding costs.
The Company continues to expand its position as one of the largest hog farming companies in Wuhan. It is intending to achieve this goal by implementing the following strategies:
We plan to grow our position as one of Wuhan’s largest hog farming companies. We intend to achieve this goal by implementing the following strategies:
- Increase hog production capacity by upgrading the genetic breeding base
- Acquire and/or construct new purebred and crossbred hog farms
- Develop a sow replacement program to continually replace less-productive sows with more productive ones
- Leverage research capabilities to breed superior breeding hogs that can be supplied to our farms and sold to other breeder farms
- Continue to strengthen brand image
Tianli Agritech, Inc. (NASDAQ: OINK) 52 week: 1.22 – 3.63 Mkt cap: 16.72M Shares: 10.14M
Read More
Stocks to Watch – The Coast Distribution System Inc. (NYSEAMEX: CRV)
The Coast Distribution System, Inc. is a known wholesale supplier of replacement parts, supplies and accessories intended for recreational vehicles (RVs) and boats in North America. It was established in June 1977. By December 2010, the Company supplied more than 11,000 products and served approximately 15,000 customers throughout the United States and Canada. It has 13 regional distribution in the United States situated in the following:
- Arizona, California ,Colorado;
- Texas, Utah ,Wisconsin;
- New York, Oregon, Pennsylvania;
- Georgia, Indiana; and
- Florida
Moreover, the Company has four regional distribution centers in Canada located in Montreal, Toronto, Calgary and Vancouver. Its customers are composed of RV and boat dealers, supply stores and service centers (Aftermarket Customers).
It carries a complete line of approximately 11,000 RV and boating parts, supplies and accessories which it purchased from more than 400 manufacturers. The Company distributes RV products such as antennae, vents, electrical items, towing equipment and hitches. This also includes appliances like air conditioners, refrigerators, ranges and generators, liquefied petroleum (LP) gas equipment, portable toilets and plumbing parts, hardware and tools, specialized recreational vehicle housewares, chemicals and supplies, and various accessories, such as ladders, jacks, fans, load stabilizers, outdoor furniture, mirrors and compressors.
The Company’s boating and marine products involve stainless steel hardware, depth sounders, anchors, life jackets and other marine safety equipment and fishing equipment that are designed primarily for use on trailer-towable boats.
Its products include those which are needed or used by RV and boating customers on a regular or recurring basis, such as trailer hitches, plastic wastewater tanks, vent lids, stabilizing jacks and battery boxes. These are distributed to the Company’s customers who are composed of:
- RV dealers
- Independent RV supply stores and service centers that purchase parts, supplies and accessories for resale to owners of RVs and for their service centers
- Independent boat dealers that purchase small accessories for new boats and replacement parts and boating supplies for resale to boat owners and operators
The Company supplies nearly 14,000 different products to more than 12,000 customers in the United States and Canada, and it also has products for the outdoor power equipment market. Our company ships the same day we receive an order, and delivers overnight or second day to nearly all major markets.
The Coast Distribution System, Inc. (NYSEAMEX: CRV) 52 week: 2.00 – 4.10 Mkt cap: 10.73M Shares: 4.61M
Read More
Stocks to Watch – Abraxas Petroleum Corp. (NASDAQ: AXAS)
Abraxas Petroleum Corporation (Abraxas) is a company involved in the acquisition, exploitation, development and production of oil and gas in the United States and Canada. It is an independent energy company established on December 31, 2010. Its net proved reserves reached 26.6 million barrels of oil equivalent and that is 50% equity interest in the proved reserves of Blue Eagle. By the year 2010, the Company daily net production is at 3,896 barrels of oil equivalent per day, of which 36% was oil or liquids.
The Company operates in four regions in the United States:
-
The Rocky Mountain
-
Mid-Continent
-
Permian Basin and onshore Gulf Coast
-
Province of Alberta, Canada
Its properties in the Rocky Mountain are situated in the Williston Basin of
North Dakota and Montana and in the Green River, Powder River and Unita Basins
of Wyoming and Utah. The Company’s wells are involved in the production of oil
and gas from different reservoirs such as the:
-
Niobrara
-
Bakken
-
Three Forks formations
The wells’ depth may range from 7,000 feet down to 12,000 feet. By the year
2010, the Company had 896 gross (104 net) producing wells in the Rocky Mountain
region. The Company’s properties are found in the Arkoma Basin and produce gas
from the Hartshorne coals at 3,000 feet.
Moreover, in the same year, it had 147 gross (33 net) producing wells in the
Mid-Continent region. The Company’s properties are in the Permian Basin region
are located in two sub-basins, the Delaware Basin and the Eastern Shelf.
Meanwhile in the Delaware Basin, the wells can be found in
-
Pecos
-
Reeves
-
Ward Counties
These wells are engaged in producing oil and gas from several stacked
formations. On the other hand, in the Eastern Shelf, the wells can be found in:
-
Coke
-
Scurry
-
Midland
-
Mitchell
-
Nolan
These wells are involved in producing oil and gas taken from the Strawn Reef
formation.
It also has 210 gross producing wells in the Permian Basin region. The
Company’s properties are found in the Edwards trend in DeWitt and Lavaca
Counties, Texas and in the Portilla field in San Patricio County, Texas. The
wells produce gas from the Edwards formation.
Abraxas Petroleum Corp. (NASDAQ: AXAS) 52 week: 1.86 – 5.29 Mkt cap: 266.83M Shares: 92.33M
Read More
Stocks to Watch – Aastrom Biosciences Inc. (NASDAQ: ASTM)
Aastrom Biosciences, Inc. (Aastrom) is a clinical development-stage company. This was established in March 1989 and is involved in research and product development. The Company focuses on developing patient specific cell products for use in regenerative medicine.
Currently, the Company is continually involved in creating expanded patient specific mixed cellular therapies for use in the treatment of severe, chronic ischemic cardiovascular diseases. Its cell-based therapies can repair or regenerate damaged or diseased tissues. The Company’s technology allows the production of mixed-cell therapies expanded from a patient’s own bone marrow and delivered directly to damaged tissues.
By the year 2010, almost 200 patients have already been treated in clinical trials utilizing the ixmyelocel-T with no treatment related serious adverse events. These medications are manufactured in the United States, a facility located in Ann Arbor, Michigan.
Moreover, these clinical development programs are intended for advancing therapies of unmet medical needs in severe, chronic ischemic cardiovascular diseases. In 2010, the Company was completing its Phase IIb clinical trial in Critical Limb Ischemia (CLI). This is a stage of peripheral arterial disease (PAD). The Company employs its dilated cardiomyopathy (DCM) program through two main types:
The first DCM is related with atherosclerotic cardiovascular disease. Meanwhile, the Non-ischemic DCM can be triggered by toxin exposure, virus or genetic diseases. This basically depends on third-parties such as ATEK Medical, LLC (ATEK), to manufacture and/or supply certain of its devices/manufacturing equipment and to manufacture and/or supply certain components, equipment, disposable devices and other materials used in its cell manufacturing process to develop its cell products.
The Company is now developing ixmyelocel-T. This is also a patientspecific,expanded multicellular therapy to manage severe chronic cardiovascular diseases. This is actually produced from a small amount of a patient’s bone marrow using a cell-expansion process. This will then lead to a multicellular therapy with an expanded population of mesenchymal stromal cells and alternately activated macrophages, which are delivered directly to the damaged tissues.
Aastrom has already advanced this main product into the late-stage clinical development. This includes a planned Phase III clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase II clinical trials in patients with dilated cardiomyopathy.
The Company’s competitors include Baxter International, Inc., Biomet, Inc., Johnson & Johnson, Inc., Miltenyi Biotec, Medtronic, Inc. and a lot more.
Aastrom Biosciences, Inc. (NASDAQ: ASTM) 52 week: 1.75 – 3.47 Mkt cap: 99.27M Shares: 38.78M
Read More
Stocks to Watch – Synergy Pharmaceuticals Inc. (NASDAQ: SGYP)
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company currently on stages of development in terms of drug manufacturing. The products are intended for the treatment of gastrointestinal (GI) disorders and diseases. Its product candidate is known as plecanatide which a guanylyl cyclase C (GC-C) receptor agonists. This can be used in the management of:
- GI disorders
- Chronic constipation (CC)
- Constipation-predominant-irritable bowel syndrome (IBS-C)
Currently, Synergy is also developing SP-333, a second generation GC-C receptor agonist used for the treatment of specific gastrointestinal inflammatory diseases like ulcerative colitis (UC). It is a synthetic analog of uroguanylin, a natriuretic hormone naturally produced in the body’s intestinal tract. Moreover, the Company is also preparing to commence a Phase 2b clinical trial of plecanatide for the treatment of IBS-C in patients.
Plecanatide (SP-304)
The Company is developing two major compounds: PLECANATIDE (SP-304) and SP-333 to treat gastrointestinal disorders and diseases. The lead investigational drug plecanatide is used for the management of Chronic Constipation. This is now in the Phase IIb/III trial and is formulated with registration criteria in mind. Moreover, its second-generation drug candidate, SP33, acts by targeting the GC-C receptors in the GI tract intended for ulcerative colitis.
Synergy’s lead investigational drug plecanatide to treat Chronic Constipation is currently in a Phase IIb/III trial, designed with registration criteria in mind. Our second-generation drug candidate, SP-333, that also targets GC-C receptors in the GI tract, is being developed to treat ulcerative colitis.
Plecanatide (formerly SP-304)
By the year 2010, the Synergy completed a Phase I study of plecanatide in the healthy volunteers and a Phase IIa clinical trial in patients for the treatment of chronic idiopathic constipation (CIC). In 2011, it started a Phase IIb/III 800-patient, 90-day randomized, 12-week, double-blind, repeated-oral-dose, placebo-controlled clinical trial of plecanatide in 880 CIC patients.
The Company announced on April 9, 2012 that it has already been successful in achieving the halfway mark for total enrollment in its ongoing plecanatide Phase II/III clinical trial in chronic idiopathic constipation (CIC) patients. Currently, approximately 800 patients are screened which resulted to a total of 440 randomized, enrolled patients to date.
This trial was designed for the enrollment of 880 patients to achieve 800 evaluable patients. This was commenced on October 24, 2011. As of now, the Company is expects completing enrollment of the trial by the third quarter of 2012.
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) 52 week: 3.17 – 9.16 Mkt cap: 212.88M Shares: 54.31M
Read More
|
|
 |
|
|
|
|
|
|
|
|
|
